TScan Therapeutics (TCRX) has entered into a term loan facility with Silicon Valley Bank, a division of First Citizens Bank, for up to $52.5 ...

Wedbush reissued their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX – Free Report) in a research report sent to investors on Monday morning,RTT News reports. The firm currently has a ...

“We’re excited to partner with TScan as they advance their innovative hematology and solid tumor programs,” said Lauren Cole, Managing Director with SVB Life Science and Healthcare Practice. “Silicon ...

Ratings for TScan Therapeutics TCRX were provided by 5 analysts in the past three months, showcasing a mix of bullish and ...

TScan Therapeutics (NASDAQ:TCRX – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $15.00 ...

TScan Therapeutics, a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, announced ...

Key Insights Significantly high institutional ownership implies TScan Therapeutics' stock price is sensitive to ...

TScan Therapeutics (TCRX) “announced that updated results from the ongoing ALLOHA Phase 1 trial of TSC-100 and TSC-101 will be presented during an oral session at the 66th American Society of ...

TScan Therapeutics, Inc. WALTHAM, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell ...

TScan Therapeutics Inc. (NASDAQ:TCRX), a biotechnology company focused on developing T cell receptor-engineered T cell (TCR-T) therapies, has been making waves in the oncology treatment landscape.

To date, event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (HR=0.28; p=0.14) No dose-limiting ...